LOGIN 

 

JOIN

 

RENEW

 

CME/MOC

Open Critical Care Grand Rounds Collective

Status Epilepticus in 2020

Summary: A discussion about status epilepticus and its causes and treatments with a further look into management of refractory status. 

Speaker: Thomas Bleck, MD, MCCM, FNCS
Professor of Neurology, Northwestern Feinberg School of Medicine
Professor Emeritus of Neurological Sciences, Neurosurgery, Medicine, and Anesthesiology, Rush Medical College

Video Editor: Kyle Swartz, DO

 

Key points

  • Status epilepticus, a continuous seizure or repetitive seizures for 30 without recovery, is generally classified as convulsive versus non convulsive. A spontaneous seizure's likelihood of progressing to status increases as its duration increases.

  • Treatment of status epilepticus initially is with intravenous Lorazepam or intramuscular Midazolam. Levetiracetam, Fosphenytoin and Valproate are all efficacious in cessation of benzodiazepine refractory seizures.

  • Refractory status epilepticus treatment can be with a benzodiazepine or propofol continuous infusion with a goal of burst suppression however burst suppression does not guarantee prevention of further seizures. In further refractory status, treatment with barbiturates or potentially ketamine can be considered.

  • Management of SE may include intubation preferably with a non-depolarizing NMJ blocking agent to avoid activating overly sensitive receptors and causing potentially fatal hyperkalemia.

 


The protocols and recommendations described in these videos do not constitute medical advice or treatment nor should they be considered replacement of the patient / physician relationship or a physicians professional judgement. ATS and the creators of the videos disclaims all liability for treatment, diagnosis, decisions and actions taken or not taken in reliance of information taken from this website.